Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema

Shetty, Rohit; Pai, Sivakami A; Vincent, Ajoy; Shetty, Nitin; Narayana, K.; Sinha, Babi; Shetty, Bhujang

doi:10.1007/s10633-007-9090-9

Cited by 34 publications

(19 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a previous study, we demonstrated that less extensive PRP is needed to control high-risk PDR if the combination of PRP and IVR is used [20], and there is also evidence that intravitreal anti-VEGF drugs can improve ERG responses if associated with reduction of retinal edema [26].…”

Section: Introductionmentioning

confidence: 97%

Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy

et al. 2012

View full text Add to dashboard Cite

To evaluate changes in electroretinographic (ERG) findings after panretinal photocoagulation (PRP) compared to PRP plus intravitreal injection of ranibizumab (IVR) in eyes with high-risk proliferative diabetic retinopathy (PDR). Patients with high-risk PDR and no prior laser treatment were assigned randomly to receive PRP (PRP group; n = 9) or PRP plus IVR (PRPplus group; n = 11). PRP was administered in two sessions (weeks 0 and 2), and IVR was administered at the end of the first laser session (week 0) in the PRPplus group. Standardized ophthalmic evaluations including (ETDRS) best-corrected visual acuity (BCVA), and fluorescein angiography to measure area of fluorescein leakage (FLA), were performed at baseline and at weeks 16 (±2), 32 (±2) and 48 (±2). ERG was measured according to ISCEV standards at baseline and at week 48 (±2). At 48 weeks, 2,400-3,000 laser spots had been placed in eyes in the PRP group, while only 1,400-1,800 spots had been placed in the PRPplus group. Compared to baseline, there was a statistically significant (P < 0.05) FLA reduction observed at all study visits in both groups, with the reduction observed in the PRPplus group significantly larger than that in the PRP group at week 48. ROD b-wave amplitude was significantly reduced to 46 ± 5% (P < 0.05) of baseline in the PRP group and 64 ± 6% (P < 0.05) in the PRPplus group. This reduction was significantly larger in the PRP group than in the PRPplus group (P = 0.024; t Test). Similar results were observed for the dark-adapted Combined Response (CR) b-wave amplitude, with a reduction at 48 weeks compared to baseline of 45 ± 4% in the PRP group and 62 ± 5% in the PRPplus group; the reduction in CR b-wave amplitude was significantly larger in the PRP group than in the PRPplus group (P = 0.0094). CR a-wave, oscillatory potentials, cone single flash, and 30 Hz flicker responses showed statistically significant within-group reductions, but no differences in between-group analyses. These results suggest that treating high-risk PDR with PRP plus IVR is effective for PDR control, and permits the use of less extensive PRP which, in turn, induces less retinal functional loss, in particular for rod-driven post-receptoral responses, than treatment with PRP alone.

show abstract

Section: Introductionmentioning

confidence: 97%

Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…It has been used to evaluate retinal function after PDT or intravitreal injection of bevacizumab for patients with AMD or with other macular diseases and has been proved to be a good measure to observe the functional changes of retina after treatment [19,32,33]. To assess objectively the influence of combined intravitreal bevacizumab and PDT on retinal function, we investigated the changes of the multifocal ERG at 1, 3 and 6 months after treatment.…”

Section: Discussionmentioning

confidence: 99%

Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy

Chen¹,

Wen²,

Li³

et al. 2009

Doc Ophthalmol

View full text Add to dashboard Cite

To investigate the changes in the multifocal electroretinography (ERG) after combined intravitreal bevacizumab and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients. Thirteen eyes of 13 patients were included in the study. The latencies and average response densities of all the six ring retinal regions were measured and compared before treatment and 1, 3, and 6 months after treatment. The latencies of the N1 and P1 waves in all the six rings remained unchanged compared with pre-treatment. Significant increase of average response densities of both P1 in ring 1 (P = 0.023) and N1, P1 in ring 2 (P = 0.028 and 0.046, respectively) were detected at 3 months post-treatment. The increase of P1 amplitude densities in ring 1 (P = 0.015) and N1, P1 amplitude densities in ring 2 (P = 0.031 and 0.034, respectively) were also significant at 6 months post-treatment. In conclusion, combined intravitreal bevacizumab and PDT is associated with an increase of multifocal ERG centrally in PCV patients.

show abstract

“…To date, there have only been short-term studies on the safety and efficacy of intravitreal bevacizumab including electrophysiological evaluation [6][7][8][15][16][17][18][19][20].…”

Section: Discussionmentioning

confidence: 99%

“…In three recent clinical studies, average mfERG macular responses in the fovea and parafovea showed increased P [1] amplitude after bevacizumab injections as compared to baseline recordings [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration

et al. 2009

View full text Add to dashboard Cite

show abstract

Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema

Cited by 34 publications

References 32 publications

Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy

Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy

Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy

Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration

Contact Info

Product

Resources

About